House to People Living with HIV, HCV and TB: “Drop Dead”
Statement condemning passage of the American Health Care Act (AHCA) today by the House of Representatives and calls for critical community action as the dangerous bill now heads to Senate.
Statement condemning passage of the American Health Care Act (AHCA) today by the House of Representatives and calls for critical community action as the dangerous bill now heads to Senate.
With growing bipartisan support for feasible measures to control skyrocketing prescription medication costs, a Health Affairs Blog post published today describes four proposals to strengthen and modernize cost control measures that already exist in the United States.
Dear Majority Leader McConnell, Minority Leader Schumer, Speaker Ryan, and Democratic Leader Pelosi: We the undersigned urge Congress to reject devastating funding cuts to the National Institutes of Health (NIH) proposed under the President’s Fiscal Year (FY) 2018 “skinny budget,” released on March 16, 2017. Of grave concern is the targeted elimination of the Fogarty International Center at NIH. This indiscriminate cut jeopardizes life-saving research required to end devastating global diseases like tuberculosis (TB) and HIV/AIDS, as well as malaria, dengue, and Ebola.
TAG strongly opposses the President’s 2018 budget blueprint, which threatens research essential to ending the epidemics of HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the United States and globally by cutting funding and eliminating programs.
Updated February 2017 The goal of hepatitis C virus (HCV) treatment is a cure (when there is no HCV in a person’s bloodstream at least 12 weeks after treatment is finished). What is Viekira XR? Viekira XR is a combination…
The global system for funding drug development socializes the costs and privatizes the pro ts though a system of taxpayer-funded research, legal corporate tax havens, and intellectual property registrations to guarantee exclusive access to markets and to reduce corporate taxes, while selling identical formulations at wildly different prices.
TAG's annual review of progress we've made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
Dear Minority Leader Pelosi: On behalf of Treatment Action Group (TAG), I write to you strongly urging for the reconsideration of your support for the passage of the 21st Century Cures Act. Even as an impending and new version of the bill is set to be introduced by Energy and Commerce Chairman, Rep. Fred Upton – we are concerned that several provisions carried from the prior iteration of the bill (H.R. 6) may continue to undermine public health and jeopardize patient safety. These concerns include lowering standards for the FDA in determining approval for prospective drugs and devices, increasing the likelihood of antimicrobial resistance, to granting extended market exclusivity for new drugs.
Health, Human Rights, and Social Justice: maximizing HIV, tuberculosis (TB), and viral hepatitis outcomes depends on the availability of state-of-the-art diagnostic and prognostic tools, engagement in expert and supportive care, and access to safe and effective drugs.
Effective responses to the burgeoning hepatitis C pandemic requires solidarity between the global North and South By Bryn Gay We can now cure the hepatitis C virus (HCV) with a coformulation of drugs that yields sustained virologic responses for all…